BrainsWay's SWIFT™ Deep TMS Data Validated, Significantly Reducing Depression Treatment Time

summarizeSummary

BrainsWay announced landmark clinical data validating its SWIFT™ Deep TMS protocol, which significantly reduces the acute treatment phase for Major Depressive Disorder by 70% while maintaining high efficacy and remission rates.

check_boxKey Events

• Accelerated Deep TMS Protocol Validated

  New clinical data for BrainsWay's SWIFT™ Deep TMS protocol for Major Depressive Disorder (MDD) shows comparable efficacy to the traditional method.

• 70% Reduction in Treatment Time

  The SWIFT™ protocol reduces the acute treatment phase from 20 visits to just 6 half-days, significantly improving patient accessibility and retention.

• High Efficacy and Remission Rates

  The accelerated protocol achieved an 87.8% response rate and a 78.0% remission rate, with a median time to remission of 21 days.

• Peer-Reviewed and FDA-Cleared

  The landmark data has been published in two peer-reviewed manuscripts in Brain Stimulation and the protocol is FDA-cleared.

auto_awesomeAnalysis

This filing reports highly positive clinical trial results for BrainsWay's accelerated Deep TMS protocol (SWIFT™), demonstrating comparable efficacy to the standard treatment but with a 70% reduction in the acute treatment phase. This innovation addresses a major barrier to patient access and retention, potentially expanding the market for Deep TMS. The peer-reviewed data and FDA clearance provide strong validation, positioning BrainsWay for increased adoption and market share in depression treatment. This development could significantly improve the company's revenue growth trajectory by making their core therapy more accessible and appealing to both patients and providers.